Mirati Therapeutics traded at $68.16 this Friday June 24th, increasing $2.27 or 3.45 percent since the previous trading session. Looking back, over the last four weeks, Mirati Therapeutics gained 17.48 percent. Over the last 12 months, its price fell by 58.51 percent. Looking ahead, we forecast Mirati Therapeutics to be priced at 66.33 by the end of this quarter and at 61.12 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
68.16
Daily Change
3.45%
Yearly
-58.51%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,707.00 2.00 0.05% -1.36%
Astellas Pharma 2,178.00 28.00 1.30% 8.39%
Eisai 5,561.00 77.00 1.40% -52.73%
Agios Pharmaceuticals 22.57 1.29 6.06% -60.21%
Alnylam Pharmaceuticals 147.50 1.20 0.82% -15.90%
Amgen 245.37 2.28 0.94% 1.11%
AstraZeneca 10,776.00 396.00 3.82% 26.79%
Bayer 57.79 -0.75 -1.28% 11.59%
BioCryst Pharmaceuticals 10.76 0.59 5.80% -37.19%
Bluebird Bio 4.40 0.12 2.80% -85.77%
Bristol-Myers Squibb 78.96 1.27 1.63% 18.31%
Exelixis 22.22 0.89 4.17% -5.12%
Gilead Sciences 63.08 0.50 0.80% -7.07%
GlaxoSmithKline 1,756.20 36.60 2.13% 24.27%
Incyte Corp 78.19 3.41 4.56% -9.95%
Ionis Pharmaceuticals 39.25 0.23 0.59% 0.82%
J&J 182.29 2.63 1.46% 11.01%
Eli Lilly 325.62 12.90 4.13% 41.44%
Merck & Co 93.13 1.13 1.23% 20.63%
Moderna Inc 144.27 1.01 0.71% -34.40%
Nektar Therapeutics 4.03 -0.13 -3.13% -76.66%
Novartis 80.60 2.37 3.03% -4.80%
Puma Biotechnology 2.85 -0.05 -1.72% -70.41%
Pfizer 51.59 1.50 2.99% 32.35%
Ultragenyx Pharmaceutical 60.57 0.58 0.97% -35.45%
Roche Holding 318.80 12.50 4.08% -7.54%
Seattle Genetics 179.33 5.33 3.06% 14.09%
Spectrum Pharmaceuticals 0.88 -0.01 -1.18% -77.38%
Sarepta Therapeutics 75.22 3.40 4.73% -6.44%

Indexes Price Day Year
USND 11608 375.43 3.34% -19.17%
US2000 1766 54.06 3.16% -24.36%

Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.